Societe Generale Upgrades AbbVie Inc. (NYSE:ABBV) to Buy

Societe Generale Upgrades AbbVie Inc. (NYSE:ABBV) to Buy

Gerber Kawasaki Wealth & Investment Management now owns 12,796 shares of the company's stock valued at $801,000 after buying an additional 1,000 shares in the last quarter. Acropolis Investment Management LLC acquired a new stake in shares of AbbVie during the second quarter worth about $106,000. Abbvie Inc now has $116.68 billion valuation. AbbVie Inc (NYSE:ABBV) has risen 10.63% since July 19, 2016 and is uptrending. It has underperformed by 6.07% the S&P500. AGEN's SI was 11.09 million shares in July as released by FINRA. Its down 6.17% from 30.96M shares previously. Baker Bros Advisors Lp accumulated 1.03% or 1.69M shares. It has underperformed by 18.96% the S&P500.

Investors sentiment increased to 1 in Q4 2016. Its down 0.05, from 1.03 in 2016Q3. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Agenus Inc (NASDAQ:AGEN). One Capital Mngmt Ltd has 0.06% invested in AbbVie Inc (NYSE:ABBV). Geode Mgmt Limited Liability Com has invested 0% in K12 Inc. Utah Retirement, a Utah-based fund reported 296,405 shares. Principal Gp Inc invested 0.01% in K12 Inc. Grandfield Dodd Lc owns 12,897 shares or 0.1% of their U.S. portfolio. E&G Advisors Ltd Partnership has 8,700 shares for 0.32% of their portfolio. Davis R M has 34,267 shares for 0.1% of their portfolio. Sandy Spring Bank & Trust owns 112,017 shares. Hsbc Public Ltd Company reported 2.16 million shares stake. Obermeyer Wood Inv Counsel Lllp stated it has 10,629 shares or 0.06% of all its holdings. Johnson Fincl Gru holds 0% or 235 shares in its portfolio. Swiss Bankshares accumulated 128,700 shares or 0% of the stock. The mean target of $71.50 should be compared with the price when the stock was languishing around $55.06 a share.

06/22/2017 - AbbVie Inc. was upgraded to " by analysts at Societe Generale. Therefore 80% are positive. LKQ had 11 analyst reports since January 15, 2016 according to SRatingsIntel. Deutsche Bank AG reissued a "hold" rating and issued a $66.00 price objective (up from $65.00) on shares of AbbVie in a report on Monday. On Thursday, July 20 the stock rating was maintained by Credit Suisse with "Hold". The company was initiated on Friday, October 7 by H.C. Wainwright. The firm has "Buy" rating given on Wednesday, December 16 by Jefferies. BMO Capital Markets maintained it with "Hold" rating and $6600 target in Wednesday, June 7 report. Stockholders of record on Friday, July 14th will be paid a dividend of $0.64 per share. Middleton & Co Inc/ma now controls 139,848 shares worth $10,140,000. KBW upgraded the shares of PHH in report on Monday, August 10 to "Outperform" rating. The company has market cap of $441.32 million. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies created to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Investors sentiment decreased to 0.98 in 2016 Q4. Its down 0.05, from 1.03 in 2016Q3. It dropped, as 86 investors sold ABBV shares while 555 reduced holdings. 99 funds opened positions while 531 raised stakes. Glenview Commercial Bank Dept owns 33,690 shares for 1.15% of their portfolio. Page Arthur B holds 11,470 shares. Accern also gave press coverage about the company an impact score of 74 out of 100, indicating that recent media coverage is likely to have an impact on the stock's share price in the next several days. 13,446 are owned by Stanley. Krasney Financial Ltd Liability Com reported 88,018 shares or 1.32% of all its holdings. Bb&T has 0.77% invested in AbbVie Inc (NYSE:ABBV). Sigma Planning Corporation holds 0.33% or 48,739 shares in its portfolio. Keating Invest Counselors Incorporated invested in 0.19% or 6,575 shares.

AbbVie Inc.is a research-based biopharmaceutical company. Tru Co Of Virginia Va has invested 0.17% of its portfolio in AbbVie Inc (NYSE:ABBV). Alpha Windward Ltd Liability Corp reported 0.2% in AbbVie Inc (NYSE:ABBV).

More news: Former FBI chief Comey sought leverage with dirty dossier, says Trump
More news: NSA Doval to visit China for BRICS meet
More news: Hillary Clinton's Approval Rating Lower Than Trump's

Among 18 analysts covering Abbvie Inc (NYSE:ABBV), 7 have Buy rating, 1 Sell and 10 Hold. Therefore 39% are positive. Abbvie Inc had 42 analyst reports since July 21, 2015 according to SRatingsIntel. Jefferies maintained AbbVie Inc (NYSE:ABBV) rating on Monday, June 26. Morgan Stanley has "Overweight" rating and $73 target. On Friday, July 14 the stock rating was maintained by Jefferies with "Buy". Inc. vs. AbbVie Inc." published on June 26, 2017 as well as Seekingalpha.com's news article titled: "AbbVie: "A Wonderful Company But At What Price?" with publication date: "June 21, 2017. The rating was maintained by Needham on Monday, June 12 with "Buy". BMO Capital Markets maintained the stock with "Market Perform" rating in Wednesday, October 28 report. The stock of State Street Corp (NYSE:STT) earned "Hold" rating by RBC Capital Markets on Thursday, June 22. The rating was initiated by Raymond James on Friday, September 2 with "Outperform".

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Thursday, April 27th. RBC Capital Markets has "Sector Perform" rating and $70 target.

Since May 10, 2017, it had 0 insider purchases, and 1 sale for $1.42 million activity. Insiders have sold a total of 278,135 shares of company stock valued at $18,841,085 in the last quarter. 5,269,109 shares of the stock were exchanged. Another trade for 38,300 shares valued at $2.50M was made by CHASE WILLIAM J on Thursday, May 18.

The stock of AbbVie Inc (NYSE:ABBV) reached all time high today, Jul, 20 and still has $79.54 target or 8.00% above today's $73.65 share price.

In other AbbVie news, EVP Carlos Alban sold 43,000 shares of AbbVie stock in a transaction that occurred on Thursday, May 4th.